News | January 03, 2025
Veeda Group rebrands as Veeda Lifesciences
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Q2 FY25 Total Income was at Rs. 85.4 crore
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Executes the first project for developing and manufacturing a novel anticancer mAb
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Subscribe To Our Newsletter & Stay Updated
